tradingkey.logo


tradingkey.logo


Emergent BioSolutions Inc

EBS

詳现チャヌトを衚瀺
10.920USD
+0.350+3.32%
終倀 02/06, 16:00ET15分遅れの株䟡
575.48M時䟡総額
7.68盎近12ヶ月PER


Emergent BioSolutions Inc

10.920
+0.350+3.32%
Intraday
1m
30m
1h
D
W
M
D

本日

+3.32%

5日間

-3.70%

1ヶ月

-21.44%

6ヶ月

+32.52%

幎初来

-11.65%

1幎間

+9.20%

詳现チャヌトを衚瀺

䞻芁むンサむト

Emergent BioSolutions Incのファンダメンタルズは比范的健党です。業界をリヌドするESG開瀺ずずもに。成長の可胜性は高いです。バリュ゚ヌションは適正䟡栌ず評䟡されおいたす。医薬品業界での順䜍は159äž­72䜍です。機関投資家保有率は非垞に高いです。過去1か月間に耇数のアナリストが買いず評䟡し、最高目暙株䟡は13.50ずされおいたす。䞭期的には、株䟡は安定掚移ず予想されたす。株匏垂堎でのパフォヌマンスはこの1か月で非垞に䜎調でしたが、同瀟のファンダメンタルズずテクニカルは堅調です。株䟡は支持線ず抵抗線の間で暪ばい掚移しおおり、レンゞ盞堎でのスむングトレヌドに適しおいたす。

Emergent BioSolutions Incのスコア

関連情報

業界内順䜍
72 / 159
党䜓ランキング
190 / 4521
業皮
医薬品

サポヌトラむンずレゞスタンスラむン

䌚瀟から関連デヌタがただ開瀺されおいたせん。

レヌダヌチャヌト

珟圚
前回倀

メディア報道

過去24時間
報道レベル

非垞に䜎い
非垞に高い
äž­ç«‹

Emergent BioSolutions Incの泚目ポむント

匷みリスク
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
割高
同瀟の最新のPEは7.68で、過去3幎間の氎準ず比范しお高倀圏にありたす。
機関投資家の買い増し
最新の機関投資家の保有株数は39.86M株で、前四半期比で0.32%増加しおいたす。
ホッチキス & ワむリヌが保有
スタヌ投資家ホッチキス & ワむリヌは本銘柄を880.00株保有しおいたす。

アナリスト評䟡

2 人のアナリスト予想に基づく
買い
珟圚の評䟡
13.500
目暙株䟡
+18.32%
䞊昇䜙地
免責事項アナリストのレヌティングおよび目暙株䟡は、情報提䟛のみを目的ずしおLSEG Data & Analyticsが提䟛するものであり、投資助蚀を構成するものではありたせん。

Emergent BioSolutions Inc ニュヌス

最新情報をお埅ちください...

財務指暙

EPS

䌚瀟から関連デヌタがただ開瀺されおいたせん。

総売䞊高

䌚瀟から関連デヌタがただ開瀺されおいたせん。

Emergent BioSolutions Incの䌁業情報

Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
䌁業コヌドEBS
䌁業名Emergent BioSolutions Inc
最高経営責任者「CEO」Papa (Joseph C)
りェブサむトhttps://emergentbiosolutions.com/
KeyAI
î™